Why IDEXX Laboratories, Inc. (IDXX) stock moved
IDEXX Laboratories, Inc. (IDXX) shares fell 2.0% to $552.46 as of July 22, 2026, a modest decline from the prior close of $563.81. BestStocks flagged the session as a material change for IDXX. Below, we break down what changed for IDXX, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
IDXX fell 2.0% to $552.46
IDXX fell 2.0% in its latest session, moving from $563.81 to $552.46.
What it means for IDEXX Laboratories, Inc. investors
For IDEXX Laboratories, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: IDEXX Laboratories, Inc. (IDXX) moved +3.42% from $557.02 to $576.07 on 2026-07-16, reaching a new 30-day high; IDEXX Laboratories, Inc. (IDXX) moved +3.02% from $540.68 to $557.02 on 2026-07-15. Weighing against that: Negative session, down 2.0%; IDEXX Laboratories, Inc. (IDXX) moved -4.17% from $564.21 to $540.68 on 2026-07-14. Wall Street's consensus price target sits at $747.50, implying +35.3% upside from $552.46. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 13 days out, the next report is the most likely near-term test of the move.
IDXX price reaction
IDXX last traded at $552.46, down $11.35 (-2.01%) from the previous close of $563.81. The session traded on 0.6× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $526.44 and $576.07, and it currently sits about 52% of the way up that band.
Bullish and bearish analyst opinions on IDEXX Laboratories, Inc. (IDXX)
The consensus analyst price target on IDEXX Laboratories, Inc. (IDXX) is $747.50, 35.3% above the recent $552.46. Over the past 90 days analysts logged 0 upgrades, 1 maintain, and 0 downgrades. Here is how the bullish and bearish cases on IDXX line up.
The bullish case
- Wall Street's consensus price target of $747.50 implies +35.3% upside from $552.46.
- The Street's most bullish target is $800.00 (+44.8%).
- IDEXX Laboratories, Inc. (IDXX) moved +3.42% from $557.02 to $576.07 on 2026-07-16, reaching a new 30-day high.
- Positive price momentum.
The bearish case
- Negative session, down 2.0%.
- IDEXX Laboratories, Inc. (IDXX) moved -4.17% from $564.21 to $540.68 on 2026-07-14.
- IDXX moved -2.56% from $570.25 to $555.67 on 2026-07-08.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 22, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for IDXX
Frequently asked questions about IDXX
Why did IDEXX Laboratories, Inc. (IDXX) stock move?
IDXX fell 2.0% to $552.46. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did IDXX stock fall?
IDXX lost 2.01% ($11.35) versus the prior close of $563.81, last trading at $552.46 on 0.6× average volume.
When is IDEXX Laboratories, Inc.'s next earnings date?
IDXX's next earnings report is estimated for 2026-08-04 — about 13 days away.
What is the analyst price target for IDXX?
The consensus analyst price target for IDXX is $747.50, about 35.3% above the current $552.46. Over the past 90 days, analysts recorded 0 upgrades, 1 maintain, and 0 downgrades.
How BestStocks tracks IDXX
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared IDXX-specific materiality thresholds, triggering an evidence check. It draws on 8 tracked change events for IDXX, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 22, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.